Could a novel GLP-1 agonist lead to longer-lasting treatment for type 2 diabetes?

New GLP-1 receptor agonists are being developed to improve blood sugar control and potentially extend dosing intervals for people with type 2 diabetes. In this episode, we examine how these medications work and how diabetes treatment is assessed in Europe.

In this episode, we cover:

• What type 2 diabetes is (insulin resistance with progressive beta-cell dysfunction)

• What GLP-1 receptor agonists do (enhance insulin secretion, reduce glucagon, slow gastric emptying)

• How newer agents aim to prolong therapeutic effect

• Evidence from clinical trials and current limitations

• Effects on weight, cardiovascular risk, and HbA1c

• Potential side effects and contraindications

• When injectable the ...